65th Berlin International Film Festival

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Hematology, Biotechnology, 65th Berlin International Film Festival, Patient, SANA, Abstract, Society, Rare-earth element, Paint, Pharmaceutical industry

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.

Key Points: 
  • SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.
  • Details of the poster presentations are as follows:

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Poster, NYSE, 65th Berlin International Film Festival, Doctor of Philosophy, Research, AM, Society, ASH, San Diego Convention Center, Diffuse large B-cell lymphoma, ADC, Abstract, Rituximab, Therapy, Manchester Grand Hyatt Hotel, Patient, Pharmaceutical industry, MD

LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.
  • "We look forward to sharing insights from the growing body of research supporting the clinical utility of ZYNLONTA as a single agent and in combination with other treatments at the 65th ASH Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • We look forward to additional details to be shared during the oral presentation.”
    Details of the oral presentation of the investigator-initiated study:
    Session: 623.
  • The abstracts are available through the ASH online meeting program.